Shares of Chromocell Therapeutics Co. (NYSE:CHRO – Get Free Report) fell 8.2% during trading on Friday . The stock traded as low as $1.57 and last traded at $1.57. 5,935 shares changed hands during ...

With $75.1 million in cash and minimal competition, aTyr Pharma is well-positioned financially, making it a compelling ...

In 2025, Cellectis will continue to focus its efforts and expenses on advancing its core clinical trials BALLI-01 and NATHALI ...

1 The total number of theoretical (or "gross”) voting rights is used as the basis for calculating threshold crossings. In ...

Redfin CEO Glenn Kelman on the benefits of joining Rocket: "Homes.com is running a Super Bowl ad, and Redfin might not be ...

We recently published a list of the 11 Best Pharma Stocks to Buy According to Hedge Funds. In this article, we are going to ...

Allakos Inc. (the "Company") (Nasdaq: ALLK), a biotechnology company that has been developing antibodies for the treatment of allergic, inflammatory ...

Mammalian genomes are organized by multi-level folding, yet how this organization contributes to cell type-specific transcription remain unclear. We uncovered that the nuclear protein SATB1 ...

In the biotechnology and chemical spaces, genus claims are often sought by patent applicants to protect not only a specific product of interest, ...

MoonLake, a clinical-stage biopharma company developing immunology therapeutics, was created by an April 2022 merger with ...

Protagonist Therapeutics, Inc.'s VERIFY and ANTHEM-UC studies show breakthroughs in polycythemia vera and ulcerative colitis.

The drugmaker Merck announced it has opened a $1 billion vaccine manufacturing facility in north Durham, a ...